Compare Eli Lilly And Co (LLY) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Weibo Corp — how do they compare? Eli Lilly And Co trades at $1,177.77 (market cap $1.04T), while Weibo Corp trades at $6.55 (market cap $1.56B). The key difference: Eli Lilly And Co is far larger — about 666.7× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.47%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Weibo Corp for 102 Days on average.
| LLY | WB | |
|---|---|---|
Market Cap | $1.04T | $1.56B |
Volume | 3,064,878 | 812,503 |
Sector | Health | Media |
52-Week High | $1.28K | $12.37 |
52-Week Low | $799.57 | $6.33 |
Typical Hold Time | 93 Days | 102 Days |
Enterprise Value | $1.09T | $786.69M |
Dividend Yield | 0.59% | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Weibo (WB) trades at $6.54, up 0.93% with bearish technical signals despite attractive valuation metrics including a P/E of 5.32 and P/B of 0.4. The company reported mixed Q2 2026 earnings with a beat on EPS but faces declining user metrics and advertising challenges. Net cash flow turned negative in 2024 at -$694M before recovering to $408M in 2025, while revenue has remained stagnant around $1.8B annually.
WB presents as a deep-value play with strong profitability margins but limited growth visibility. The stock's upside depends on advertising recovery and user engagement stabilization, though competitive pressures and China's regulatory environment pose significant risks. Analyst consensus is divided with 41% buy ratings, reflecting uncertainty about the company's ability to reignite growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
